Wednesday, June 05, 2024 The CX6 trial (SENTICOL III) an international validation study of sentinel node biopsy in early cervical cancer has closed to further accrual having met the accrual target with 988 study participants enrolled.SENTICOL III is large prospective multicenter international randomized study designed to validate the Sentinel Lymph Node (SLN) mapping technique in early cervical cancer. This "validation study" will compare the outcome of patients with negative SLN (experimental arm) vs patients with negative SLN + Pelvic Lymph Node dissection (PLN)(reference arm). For more information please visit the CX5 members trial page.
